AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1632701 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral OK-432 with preserved spleen
Number of subjects: 970
Study 6499513 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pivmecillinam twice-daily for 3 days
Number of subjects: 183
Study 6499513 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pivmecillinam twice-daily for 7 days
Number of subjects: 183
Study 30817066 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP 75 IU/kg Q7D
Number of subjects: 55
Study 30817066 — intervention group
Group type: COMPARATOR
Intervention: N8-GP 50 IU/kg Q4D
Number of subjects: 55
Study 28717855 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cisplatin and 5-fluorouracil (PF) with radiotherapy (RT)
Number of subjects: 131
Study 24781891 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cardiopulmonary exercise test (CPET)
Number of subjects: 40
Study 24273298 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground gait training
Number of subjects: 26
Study 24273298 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training
Number of subjects: 26
Study 21340661 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin qd for 5 days, then 0.25 mg digoxin qd plus 5 mg linagliptin qd for 6 days
Number of subjects: 20
Study 21340661 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg digoxin qd for 11 days
Number of subjects: 20
Study 19713201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone escape
Number of subjects: 302
Study 19713201 — intervention group
Group type: EXPERIMENTAL
Intervention: High urinary aldosterone
Number of subjects: 302
Study 19713201 — intervention group
Group type: COMPARATOR
Intervention: Low aldosterone counterparts
Number of subjects: 302
Study 16361060 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Stimulation (AS) while performing Cognitive Task (CT)
Number of subjects: 60
Study 16361060 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat Stimulation (HS) at 46 degrees C for 6 minutes
Number of subjects: 60
Study 16361060 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Stimulation (AS) and Heat Stimulation (HS)
Number of subjects: 60
Study 16361060 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Stimulation (AS), Heat Stimulation (HS), and Cognitive Task (CT)
Number of subjects: 60
Study 16361060 — intervention group
Group type: COMPARATOR
Intervention: Control group (AS + HS)
Number of subjects: 60
Study 12544367 — intervention group
Group type: EXPERIMENTAL
Intervention: Notoginseny cream
Number of subjects: 65
Study 12544367 — intervention group
Group type: COMPARATOR
Intervention: Hirudoid cream (Control)
Number of subjects: 65
Study 10787394 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate 666 mg three times/day
Number of subjects: 581
Study 10787394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study 8741298 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Lubricath Foley Catheter
Number of subjects: 12
Study 8741298 — intervention group
Group type: COMPARATOR
Intervention: Silicone-coated catheter
Number of subjects: 12
Study 1626496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 1626496 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 5 g/day
Number of subjects: 152
Study 1626496 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 10 g/day
Number of subjects: 152
Study 1626496 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 15 g/day
Number of subjects: 152
Study 6383234 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90
Number of subjects: 0
Study 6383234 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone hexacetonide
Number of subjects: 0
Study 31892668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) applied to the ipsilesional motor cortex (M1) (600 pulses)
Number of subjects: 150
Study 31892668 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation (coil placement over the parieto-occipital vertex)
Number of subjects: 150
Study 31892668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 150
Study 29673362 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 65
Study 29673362 — intervention group
Group type: EXPERIMENTAL
Intervention: Coalition strategy
Number of subjects: 65
Study 27852965 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (100 mg, 200 mg, and 400 mg for two weeks each)
Number of subjects: 41
Study 27852965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24937016 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (monthly counseling phone calls, weekly mailings with tailored and non-tailored materials, videos)
Number of subjects: 0
Study 24937016 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (five informational handouts on weight loss)
Number of subjects: 0
Study 22100204 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of misoprostol sublingually
Number of subjects: 530
Study 22100204 — intervention group
Group type: COMPARATOR
Intervention: 10 units of oxytocin intramuscularly
Number of subjects: 530
Study 20370840 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin therapy
Number of subjects: 240
Study 17683324 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration anaesthesia
Number of subjects: 76
Study 17683324 — intervention group
Group type: COMPARATOR
Intervention: No local infiltration anaesthesia
Number of subjects: 76
Study 16221145 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular non-invasive probe
Number of subjects: 140
Study 16221145 — intervention group
Group type: EXPERIMENTAL
Intervention: Microinvasive electrodes
Number of subjects: 140
Study 12374540 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-10 (20 micro g/kg) subcutaneously 3 times weekly for 12 weeks
Number of subjects: 28
Study 12374540 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously 3 times weekly for 12 weeks
Number of subjects: 28
Study 12374540 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-10
Number of subjects: 28
Study 10437875 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 10437875 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 7755112 — intervention group
Group type: EXPERIMENTAL
Intervention: Course-based diagnostic classification system for major depression
Number of subjects: 524
Study 7755112 — intervention group
Group type: EXPERIMENTAL
Intervention: Course-based diagnostic classification system for dysthymia
Number of subjects: 524
Study 7755112 — intervention group
Group type: EXPERIMENTAL
Intervention: Course-based classification system for major depression
Number of subjects: 524
Study 7755112 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability for six course of illness specifiers
Number of subjects: 524
Study 7755112 — intervention group
Group type: EXPERIMENTAL
Intervention: Current or lifetime major depression or dysthymia
Number of subjects: 524
Study 2106162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 2 g/m2 days 1 to 4 with mesna uroprotection
Number of subjects: 124
Study 2106162 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, ifosfamide, dacarbazine at doses of 60, 7,500, and 900 mg/m2 respectively by continuous infusion over 72 hours
Number of subjects: 124
Study 2106162 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and dacarbazine alone
Number of subjects: 124
Study 2106162 — intervention group
Group type: COMPARATOR
Intervention: Observation in the adjuvant treatment of high-grade sarcomas
Number of subjects: 124
Study 6154838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 6154838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine + Diuretic
Number of subjects: 0
Study 6154838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine + Diuretic + Vasodilator
Number of subjects: 0
Study 31162860 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified oxygen therapy
Number of subjects: 188
Study 31162860 — intervention group
Group type: COMPARATOR
Intervention: Non-humidified oxygen therapy
Number of subjects: 188
Study 29089293 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives to both the expectant mother and her support person
Number of subjects: 0
Study 29089293 — intervention group
Group type: COMPARATOR
Intervention: Incentives to the expectant mother alone
Number of subjects: 0
Study 25758990 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF non‐male factor (IVF/NMF)
Number of subjects: 243
Study 25758990 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI non‐male factor (ICSI/NMF)
Number of subjects: 243
Study 25758990 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI male factor (ICSI/MF)
Number of subjects: 243
Study 23614176 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential training using cross‐cultural movies and focused group discussions, 8 group sessions conducted.
Number of subjects: 9
Study 23614176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 9
Study 21295417 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.32% DHA, 0.64% DHA, 0.96% DHA (DHA-supplemented formulas)
Number of subjects: 181
Study 21295417 — intervention group
Group type: COMPARATOR
Intervention: Control (0% DHA)
Number of subjects: 181
Study 19268506 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol (2mg) + trimegestone (0.5mg)
Number of subjects: 184
Study 19268506 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol (2mg) + dydrogesterone (10mg)
Number of subjects: 184
Study 18393784 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 0
Study 18393784 — intervention group
Group type: EXPERIMENTAL
Intervention: Masking
Number of subjects: 0
Study 18393784 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation concealment
Number of subjects: 0
Study 18393784 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted randomization
Number of subjects: 0
Study 18393784 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for prognostic variables
Number of subjects: 0
Study 18393784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat approach
Number of subjects: 0
Study 11984090 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CH plus IPHHOI combined with surgery (M-CH1+IPHHOI group)
Number of subjects: 79
Study 11984090 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 79
Study 10413119 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD (anterior cervical discectomy)
Number of subjects: 84
Study 10413119 — intervention group
Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy with fusion)
Number of subjects: 84
Study 7605521 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics
Number of subjects: 1734
Study 7605521 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillinase-resistant antibiotics
Number of subjects: 1734
Study 7605521 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 1734
Study 2257957 — intervention group
Group type: COMPARATOR
Intervention: 300 mg/day ranitidine plus placebo (group I)
Number of subjects: 352
Study 2257957 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day ranitidine plus 50 mg/day pirenzepine (group II)
Number of subjects: 352
Study 2257957 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day ranitidine plus 100 mg/day pirenzepine (group III)
Number of subjects: 352
Study 2257957 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (analgesic activity)
Number of subjects: 352
Study 453054 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric requirements for weight gain
Number of subjects: 29
Study 29674981 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care with placebo
Number of subjects: 60
Study 29674981 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine alone
Number of subjects: 60
Study 29674981 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care with pain medication
Number of subjects: 60
Study 29674981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication (paracetamol, COX inhibitors, pregabalin)
Number of subjects: 60
Study 28233311 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA-1 phototherapy at 30 J/cm2, escalated to 60 J/cm2 if hair regrowth was <75%, and further escalated to 120 J/cm2 if necessary; total of 25 sessions administered.
Number of subjects: 22
Study 28233311 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA-1 phototherapy
Number of subjects: 22
Study 24547881 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 30 mg/day
Number of subjects: 31
Study 24547881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 24222837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track (FT) group
Number of subjects: 399
Study 24222837 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Care (OC) group
Number of subjects: 399
Study 24222837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 399
Study 21415430 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol combinations (remifentanil 0.8 to 1.6 ng · mL(‐1) and propofol 1.5 to 2.7 μg · mL(‐1))
Number of subjects: 24
Study 21415430 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol combinations (remifentanil approximately 3.0 to 4.0 ng · mL(‐1) and propofol 0.0 to 1.1 μg · mL(‐1))
Number of subjects: 24
Study 21415430 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol combinations
Number of subjects: 24
Study 18362863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk behaviors (e.g., > or =2 heterosexual partners in the past year, younger age at sexual debut)
Number of subjects: 658
Study 18362863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk behaviors (e.g., > or =2 heterosexual partners in the past year, enrolling both sex and drug network members)
Number of subjects: 658
Study 18362863 — intervention group
Group type: COMPARATOR
Intervention: Condom use at last sex
Number of subjects: 658
Study 18362863 — intervention group
Group type: COMPARATOR
Intervention: Substance abuse (methamphetamine use)
Number of subjects: 658
Study 18362863 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of STIs
Number of subjects: 658
Study 18362863 — intervention group
Group type: EXPERIMENTAL
Intervention: STI types
Number of subjects: 658
Study 16608139 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutrition supplement (200 ml) once daily immediately after diagnosis of infection
Number of subjects: 34
Study 16608139 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (enriched food after referral to a dietician)
Number of subjects: 34
Study 14710063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 44
Study 14710063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10450257 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline at 80-120 ng/ml
Number of subjects: 41
Study 10450257 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline at 40-60 ng/ml
Number of subjects: 41
Study 7558388 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Grade Silicone Rubber (MSR) with an oval 15 mm clamp, volume of 0.1531 +/- 0.0059 ml injected by five to six turns of the applicator handwheel.
Number of subjects: 122
Study 7558388 — intervention group
Group type: COMPARATOR
Intervention: No-scalpel vasectomy (control group).
Number of subjects: 122
Study 2328190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan and mephenytoin coadministration
Number of subjects: 48
Study 2328190 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of mephenytoin and dextromethorphan
Number of subjects: 48
Study 2328190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 48
Study 486628 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (n = 22)
Number of subjects: 33
Study 486628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 33
Study 31812334 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Re‐Engineered Discharge (RED) intervention
Number of subjects: 0
Study 31812334 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched SNFs without RED intervention)
Number of subjects: 0
Study 31774051 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier vaccination
Number of subjects: 0
Study 31774051 — intervention group
Group type: COMPARATOR
Intervention: Later vaccination
Number of subjects: 0
Study 29059426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 980
Study 29059426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 980
Study 29059426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor VEGF-A
Number of subjects: 980
Study 26670076 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral dose adjusted ovarian drilling (ULOD) using 60 Joules/cm(3) applied to the larger ovary
Number of subjects: 105
Study 26670076 — intervention group
Group type: COMPARATOR
Intervention: Bilateral ovarian drilling (BLOD) with fixed doses of 1200 J
Number of subjects: 105
Study 25141218 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser+EX (diode laser 980 nm, 20 W, fluence 37.5 J/cm², total energy 1200 J, thrice weekly for 3 weeks)
Number of subjects: 100
Study 25141218 — intervention group
Group type: COMPARATOR
Intervention: EX (placebo laser therapy plus daily exercises)
Number of subjects: 100
Study 22381711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 60/120 mg daily
Number of subjects: 506
Study 22381711 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50/100 mg daily
Number of subjects: 506
Study 20503802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical model for predicting protocol performance
Number of subjects: 0
Study 17224031 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group: primary galvanic caps fabricated on implant abutments with a secondary cast noble alloy superstructure luted with resin cement (Nimetic Cem)
Number of subjects: 50
Study 17224031 — intervention group
Group type: COMPARATOR
Intervention: Control group: prefabricated burn-out caps used for casting the metal frameworks, cemented with resin cement (Panavia 21)
Number of subjects: 50
Study 15617592 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple decompression (Group A)
Number of subjects: 70
Study 15617592 — intervention group
Group type: COMPARATOR
Intervention: Anterior deep submuscular transposition (Group B)
Number of subjects: 70
Study 12518488 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro (experimental battery-powered toothbrush)
Number of subjects: 127
Study 12518488 — intervention group
Group type: COMPARATOR
Intervention: Colgate Navigator (control manual toothbrush)
Number of subjects: 127
Study 12518488 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B CrossAction (control manual toothbrush)
Number of subjects: 127
Study 12518488 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B CrossAction
Number of subjects: 127
Study 12518488 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro
Number of subjects: 127
Study 9876347 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 8
Study 9876347 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment
Number of subjects: 8
Study 7625363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (24% fat)
Number of subjects: 105
Study 7625363 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (46% fat)
Number of subjects: 105
Study 30307818 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic inspiratory pressure-threshold loading (PTL) to task failure followed by a constant load submaximal time-to-exhaustion (TTE) exercise test at 85% of the predetermined peak work rate.
Number of subjects: 18
Study 30307818 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no prior induced DF).
Number of subjects: 18
Study 27188702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic OTO‐201
Number of subjects: 532
Study 27188702 — intervention group
Group type: COMPARATOR
Intervention: Sham (tympanostomy tubes alone)
Number of subjects: 532
Study 26286684 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive focussing on treatment information
Number of subjects: 146
Study 26286684 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative focussing on treatment information
Number of subjects: 146
Study 26286684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed aspects focussing on treatment information
Number of subjects: 146
Study 26286684 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant information focussing
Number of subjects: 146
Study 21859748 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program for 6 months
Number of subjects: 52
Study 21859748 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining usual lifestyle behaviors
Number of subjects: 52
Study 21364149 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (Cypher group)
Number of subjects: 226
Study 21364149 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (Taxus group)
Number of subjects: 226
Study 21364149 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (Endeavor group)
Number of subjects: 226
Study 21364149 — intervention group
Group type: COMPARATOR
Intervention: Endeavor stent
Number of subjects: 226
Study 19805650 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 2650
Study 19805650 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome event (composite of nonfatal myocardial infarction, nonfatal ischemic stroke, major amputation, and cardiovascular death)
Number of subjects: 2650
Study 16886933 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine without aura (MoA)
Number of subjects: 0
Study 16886933 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA)
Number of subjects: 0